I'm LongbridgeAI, I can summarize articles.CID Holdco pre-market down 15.29%; Atlantic pre-market up 14.30%; Gamehaus pre-market up 94.99%; Ai Rui Electronics pre-market up 59.00%; Nurix Therapeutics pre-market up 53.14%
Pre-market Hot Trades in US Stocks
CID Holdco is down 15.29% in pre-market trading. Based on recent key news:
- On June 6, CID Holdco announced a 1-for-25 reverse stock split. This move may impact stock performance, leading to a 2.11% drop in after-hours trading and a 20.39% decline during regular trading hours. Source: Zhitong Finance. Recent market volatility is significant, and investors should exercise caution.
Atlantic is up 14.30% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows notable volatility, and specific reasons need further observation.
Top Gainers in Pre-market US Stocks
Gamehaus is up 94.99% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows notable volatility, and specific reasons need further observation.
Airoha Technology is up 59% in pre-market trading. There is no significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows notable volatility, and specific reasons need further observation. no_news
Nurix Therapeutics is up 53.14% in pre-market trading. Based on recent key news:
-
On June 8, Nurix Therapeutics reached a licensing and collaboration agreement with Swiss pharmaceutical giant Roche worth up to $2.3 billion, focusing on the development of the blood cancer drug bexobrutideg. This agreement includes a $7 million upfront payment and potential milestone payments for development, regulatory, and sales, significantly boosting the stock price.
-
On June 8, the bexobrutideg drug developed in collaboration with Roche showed significant anti-cancer activity in early clinical trials, with an overall response rate of 83.3% among patients, further enhancing market confidence in the drug and promoting stock price increases.
-
On June 8, analysts noted that Roche's collaboration with Nurix would strengthen Roche's advantages in hematology and provide cross-therapeutic opportunities to expand its influence in immunology and neurology, with the market positively evaluating the strategic significance of this collaboration, driving stock price increases. The trend of collaboration in the biopharmaceutical industry is strengthening, with significant capital inflows